Confirmation of the development potential of Amoeba in cosmetics

Significant results of the study carried out on 30 patients by the Institut d’Expertise Clinique

Chassieu (France), June 10, 2024 – 5:45pm – AMOÉBA (FR0011051598 – ALMIB), an industrial greentech specialised in the treatment of microbiological risk, developing a biocontrol agent for the protection of plants in agriculture and a range of cosmetic ingredients, announces that it has received the results of the clinical study confirming the interest of using its ingredient in cosmetic as a skin care product.

In October 2023, following tests of its ingredient on artificial skin which showed excellent results, Amoéba announced the launch of a major new application in the field of cosmetics (see press release of October 16, 2023).

An initial clinical study was carried out by the Institut d’Expertise Clinique on 30 volunteers (half-face, n=60) in March and April 2024. This study confirmed the benefits of using our ingredient in skin care cosmetics, with ‘statistically significant’ results justifying the following claims:

  • ‘improved dermis thickness’.
  • ‘restoring effect on the superficial dermis’.
  • ‘improvement in skin density’.
  • ‘improved dermal texture’.

Amoéba has also obtained the inclusion of this active ingredient on the INCI list (International Nomenclature for Cosmetic Ingredients), paving the way for marketing and the search for commercial partnerships without any further authorization being required.

The skincare market is estimated to be worth 200 billion dollars in 2023, with expected annual growth of 6% until 2030 (source: McKinsey – The beauty market in 2023).

Amoéba’s management will have the opportunity to present its strategy on June 12 in Paris at the annual Portzamparc BNP Paribas Group Mid & Small Caps Conference. The presentation used for this event will be available online on the company’s website at the latest by 7pm on Tuesday June 11.